Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2010

View Archived Issues

GlaxoSmithKline presents new calcium receptor antagonists

Pfizer describes novel AMPA receptor agonists

Humoral responses to DC-Melvac cancer vaccine seen in melanoma patients

Hepatitis C treatment SCY-635 associated with a high barrier to resistance

INT-747 promising as add-on therapy to ursodeoxycholic acid for primary biliary cirrhosis

Updated phase I data disclosed on IMO-2125 in HCV infection

EMD-1214063 displays potent and selective c-Met inhibition

Telik presents novel Aurora A/B and VEGFR-2 inhibitors

Dual TLR7 and TLR9 antagonist has therapeutic effects in mouse model of atherosclerosis

New FAAH inhibitors claimed by Renovis

Novartis reports R&D highlights for first quarter of 2010

Temozolomide shows activity in pituitary tumors and carcinomas

Oncolytics Biotech completes phase I enrollment for phase I/II Reolysin trial

FDA recommends reformulation of UCB's Neupro

Nycomed and Merck & Co. collaborate on commercialization of roflumilast in Canada and Europe

EMA's CHMP recommends extending indication of tocilizumab

ALK to acquire Fornix Biosciences' allergy division in The Netherlands

Penwest provides update on focused business plan

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

New FDA initiative to reduce risks related to infusion pumps

Presidio and Numerate end HCV research collaboration

Michael J. Fox Foundation awards grants to advance Parkinson's disease research

Stem Cell Therapeutics completes 90-day endpoint period for REGENESIS trial

ACT completes studies to support phase I stem cell trial in SMD

AD-02 Alzheimer's vaccine progresses to phase II

CHMP recommends conditional marketing approval for Votrient

Proteo completes patient recruitment in phase II Elafin trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...